This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Achillion Hasn't Stopped Aching

The Street will be looking for a loss of 16 cents per share on virtually no revenue. That's not an error. In the third quarter, for instance, the company didn't recognize any revenue. Nor did Achillion recognize any revenue in the year-ago quarter. Therein lays the problem with speculative biotechs.

As much as you would like to believe revenue is not an important metric, you have to remember profits don't just magically appear without sales. And how long will investors wait for this company to emerge out of this perpetual "development stage?"

Analysts have been bullish over the past quarter and have steadily raised estimates. If Achillion can continue to grow earnings, it's a great thing. But it doesn't change the fact that this company remains a speculative play, at best. Even if the numbers do come out better-than-expected, it doesn't reduce the risk.

What's important here is what management says about the company's hepatitis-C drug. This is where the emphasis must be placed. I'm curious to hear what management says about ACH-3102, which is a second-generation inhibitor of hepatitis-C. It is believed that ACH-3102 has more enhanced resistance capabilities when compared to first-generation inhibitors. I'd like to know how close the company is to development.

What's more, management has spoken highly of ACH-3422, which is a preclinical compound designed to inhibit HCV NS5B polymerase, a form of the hepatitis C virus. Management had promised to begin in-human studies of this new nomination by the first half of 2014. Any positive outlook to these drugs will be encouraging. But impressing the FDA is a separate matter.

There is some hope here. My concern, however, is with the recent exuberance in the stock. It's a mistake to buy these shares before any real announcement about when the new drugs will come to market.

At the time of publication, the author was long AAPL but held no position in any of the other stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACHN $10.07 -1.10%
AAPL $117.29 -0.85%
FB $107.07 2.70%
GOOG $766.64 3.20%
TSLA $237.30 3.10%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.08 +21.67 1.04%
NASDAQ 5,154.7850 +46.1190 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs